At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KURE KraneShares MSCI All China Health Care Index ETF
Market Closed 10-23 16:00:00 EDT
17.85
+0.35
+2.00%
盘后17.85
+0.000.00%
19:30 EDT
High17.85Low17.65Vol47.08K
Open17.65D1 Closing17.50Amplitude1.14%
Mkt Cap111.54MTradable Cap111.54MTotal Shares6.25M
T/O835.58KT/O Rate0.75%Tradable Shares6.25M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

What WuXi Biologics Buyers Were Betting On
Simply Wall St.  ·  10-24 13:38
What WuXi Biologics Buyers Were Betting On
Why Innovent Biologics (SEHK:1801) Is Back In The Spotlight
Simply Wall St.  ·  10-24 13:38
Why Innovent Biologics (SEHK:1801) Is Back In The Spotlight
Innovent Biologics - Registrational Phase 3 G-Hope-001 Study Met Both Primary Endpoints
THOMSON REUTERS  ·  10-23 20:00
Innovent Biologics - Registrational Phase 3 G-Hope-001 Study Met Both Primary Endpoints
Innovent Biologics: Arcotatug Tavatecan Demonstrated Favorable Safety Profile, with a Low Incidence of Gastrointestinal Adverse Events
THOMSON REUTERS  ·  10-23 20:00
Innovent Biologics: Arcotatug Tavatecan Demonstrated Favorable Safety Profile, with a Low Incidence of Gastrointestinal Adverse Events
Schroders Limited Raises Stake in Innovent Bio by 926,500 Shares at HK$88.26 Each
Stock News  ·  10-23 19:28
Schroders Limited Raises Stake in Innovent Bio by 926,500 Shares at HK$88.26 Each
Alert on Innovent Biologics Phase 3 Study Results Withdrawn
Reuters  ·  10-23 19:14
Alert on Innovent Biologics Phase 3 Study Results Withdrawn
Innovent's Arcotatug Tavatecan Meets Survival Endpoints in Phase 3 Gastric Cancer Trial
Reuters  ·  10-23 18:10
Innovent's Arcotatug Tavatecan Meets Survival Endpoints in Phase 3 Gastric Cancer Trial
2026 Esmo Lba | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (Cldn18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of Pfs and Os
THOMSON REUTERS  ·  10-23 18:10
2026 Esmo Lba | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (Cldn18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of Pfs and Os
1 Boom in China, India, Brazil Could Create $22 Bln Market by 2035, J.P. Morgan Says
Reuters  ·  10-23 17:55
1 Boom in China, India, Brazil Could Create $22 Bln Market by 2035, J.P. Morgan Says
Wuxi Biologics (Cayman) Stock Rises 1.2% in Hong Kong
Dow Jones  ·  10-23 16:33
Wuxi Biologics (Cayman) Stock Rises 1.2% in Hong Kong
Morgan Stanley: Preview of Q4 Catalysts for Chinese Biotech Stocks, Sector Rated "Attractive"
Stock News  ·  10-23 15:18
Morgan Stanley: Preview of Q4 Catalysts for Chinese Biotech Stocks, Sector Rated "Attractive"
CSPC Pharma's Injection for Rare Autoimmune Disease Gets Regulatory Nod in China
MT Newswires Live  ·  10-23 12:30
CSPC Pharma's Injection for Rare Autoimmune Disease Gets Regulatory Nod in China
China's Innovative Drugs Take Center Stage Globally as Multiple Pipelines Hit Key Data Milestones, Says Guosheng Securities
Stock News  ·  10-23 11:08
China's Innovative Drugs Take Center Stage Globally as Multiple Pipelines Hit Key Data Milestones, Says Guosheng Securities
CSPC Pharmaceutical Wins China Approval for Batoclimab to Treat Generalized Myasthenia Gravis
Reuters  ·  10-23 08:02
CSPC Pharmaceutical Wins China Approval for Batoclimab to Treat Generalized Myasthenia Gravis
CSPC Pharmaceutical - Batoclimab Injection (Enlida) Obtains Drug Registration Certificate from Nmpa
THOMSON REUTERS  ·  10-23 08:01
CSPC Pharmaceutical - Batoclimab Injection (Enlida) Obtains Drug Registration Certificate from Nmpa
US proposes curbs on investment in Chinese biotech firms
Madison Muller & Amber Tong / Bloomberg   ·  10-23 04:38
US proposes curbs on investment in Chinese biotech firms
CSPC Pharmaceutical - Pharma Initiates Phase Iii Trial of Sys6043 for Triple-Negative Breast Cancer in China
THOMSON REUTERS  ·  10-22 18:32
CSPC Pharmaceutical - Pharma Initiates Phase Iii Trial of Sys6043 for Triple-Negative Breast Cancer in China
CSPC Pharma (01093) Launches Phase II Trial in China for SYH2066 Tablets Targeting RSV Infection
Stock News  ·  10-22 18:30
CSPC Pharma (01093) Launches Phase II Trial in China for SYH2066 Tablets Targeting RSV Infection
CSPC Pharmaceutical Says Phase II Trial of Syh2066 Officially Initiated in China
Reuters  ·  10-22 18:28
CSPC Pharmaceutical Says Phase II Trial of Syh2066 Officially Initiated in China
CSPC Pharmaceutical - Phase Ii Clinical Trial of Syh2066 for Treatment of Respiratory Syncytial Virus Infection Officially Initiated in China
THOMSON REUTERS  ·  10-22 18:26
CSPC Pharmaceutical - Phase Ii Clinical Trial of Syh2066 for Treatment of Respiratory Syncytial Virus Infection Officially Initiated in China

Introduction

Company Name.
KraneShares MSCI All China Health Care Index ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in instruments in its underlying index or in instruments that have economic characteristics similar to those in the underlying index. The underlying index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint, which is designed to measure the equity market performance of Chinese companies in the healthcare sector. The fund is non-diversified.
Issue price:
--